Bioventus received FDA clearance for Durolane, a single injection hyaluronic acid device used for joint lubrication in the treatment of knee osteoarthritis pain.
Here are three key points:
1. Durolane also includes Gelsyn-3, a three injection hyaluronic acid device, and Supartz FX, a five injection hyaluronic acid device.
2. Bioventus plans to maket Durolane in the U.S. in early 2018. The company is currently marketing Durolane in more than 25 countries globally.
3. CEO of Bioventus Tony Bihl said, "Durolane has been a proven knee [osteoarthritis] pain reliever for mare than 15 years, improving the lives of more than 1 million people worldwide. It will join our current offerings to provide even more efficacious treatment options for U.S. patients, physicians and payers."